Free Trial
LON:ONC

Oncimmune (ONC) Share Price, News & Analysis

Oncimmune logo
GBX 1.14 0.00 (0.00%)
As of 03/17/2025

About Oncimmune Stock (LON:ONC)

Key Stats

Today's Range
1.14
1.14
50-Day Range
1.14
12.20
52-Week Range
1.01
31
Volume
N/A
Average Volume
589,365 shs
Market Capitalization
£1.29 million
P/E Ratio
0.13
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Leeds, the United Kingdom.

Remove Ads
Receive ONC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncimmune and its competitors with MarketBeat's FREE daily newsletter.

ONC Stock News Headlines

Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
Oncimmune Share Chat (ONC)
See More Headlines

ONC Stock Analysis - Frequently Asked Questions

Oncimmune's stock was trading at GBX 14.35 at the beginning of 2025. Since then, ONC stock has decreased by 92.1% and is now trading at GBX 1.14.
View the best growth stocks for 2025 here
.

Oncimmune Holdings plc (LON:ONC) announced its earnings results on Monday, February, 10th. The company reported ($4.72) earnings per share for the quarter. Oncimmune had a negative trailing twelve-month return on equity of 2,277.74% and a net margin of 581.63%.

Shares of ONC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncimmune investors own include B&M European Value Retail (BME), Coats Group (COA), 4D pharma (DDDD), genedrive (GDR), Greencore Group (GNC), Intel (INTC) and IQE (IQE).

Company Calendar

Last Earnings
2/10/2025
Today
4/02/2025

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
LON:ONC
CIK
N/A
Fax
N/A
Employees
52
Year Founded
N/A

Profitability

Trailing P/E Ratio
0.13
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£10.79 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£1.86 million
Cash Flow
GBX 0.10 per share
Price / Cash Flow
11.96
Book Value
GBX (1.72) per share
Price / Book
-0.66

Miscellaneous

Free Float
N/A
Market Cap
£1.29 million
Optionable
Not Optionable
Beta
1.19
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (LON:ONC) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners